Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer

NCT07534033 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Diagnosed by Histology or Cytology
A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
Overall Lung Function is Adequate for the Planned Lung Resection
AJCC is Classified as IB-IIIC

Interventions

DRUG: Probiotics combined with neoadjuvant chemoimmunotherapy

Sponsor

Zhujiang Hospital